Oncolytics Biotech

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ONCY and other ETFs, options, and stocks.

About ONCY

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolation of the reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. 

CEO
Jared Kelly
CEOJared Kelly
Employees
29
Employees29
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1998
Founded1998
Employees
29
Employees29

ONCY Key Statistics

Market cap
63.34M
Market cap63.34M
Price-Earnings ratio
-1.83
Price-Earnings ratio-1.83
Dividend yield
—
Dividend yield—
Average volume
1.94M
Average volume1.94M
High today
$0.55
High today$0.55
Low today
$0.4851
Low today$0.4851
Open price
$0.55
Open price$0.55
Volume
1.34M
Volume1.34M
52 Week high
$1.32
52 Week high$1.32
52 Week low
$0.4414
52 Week low$0.4414

Stock Snapshot

Oncolytics Biotech(ONCY) stock is priced at $0.50, giving the company a market capitalization of 63.34M. It carries a P/E multiple of -1.83.

As of 2026-10-17, Oncolytics Biotech(ONCY) stock has fluctuated between $0.49 and $0.55. The current price stands at $0.50, placing the stock +3.1% above today's low and -9.1% off the high.

The Oncolytics Biotech(ONCY)'s current trading volume is 1.34M, compared to an average daily volume of 1.94M.

During the past year, Oncolytics Biotech(ONCY) stock moved between $0.44 at its lowest and $1.32 at its peak.

During the past year, Oncolytics Biotech(ONCY) stock moved between $0.44 at its lowest and $1.32 at its peak.

ONCY News

Investing.com 3d
Oncolytics reports GOBLET study enrollment complete - Investing.com

...

Oncolytics reports GOBLET study enrollment complete - Investing.com
TipRanks 3d
Oncolytics should be bought amid recent weakness, says Lake Street

Lake Street analyst Chad Messer notes Oncolytics (ONCY) reported that a new method of use patent covering pelareorep as an immunotherapy for the treatment of ca...

TipRanks 5d
Oncolytics Biotech Extends Pelareorep Patent Protection Into Late 2040s

Oncolytics Biotech ( (ONCY) ) has issued an update. Oncolytics Biotech has strengthened its intellectual property position around pelareorep by securing new me...

People also own

Based on the portfolios of people who own ONCY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.